T-cell engager antibodies (TCEs) redirect cytotoxic T-cells to tumor cells by simultaneously binding to a component of the TCR complex (commonly CD3E) and a tumor associated antigen (TAA) on tumor cells [1]. Here, CD3E is linked to neoplasm.